Bvf Inc Contrafect Corp Transaction History

Bvf Inc

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$0.18 - $3.51 $630,000 - $12.3 Million	-3,500,000 Reduced 88.11%	472,300 $79,000
Q2 2021 Aug 16, 2021	BUY	$3.58 - $4.9 $572,800 - $784,000	160,000 Added 4.2%	3,972,300 $17.5 Million
Q1 2021 May 17, 2021	BUY	$4.46 - $6.68 $9.87 Million - $14.8 Million	2,212,300 Added 138.27%	3,812,300 $18.3 Million
Q2 2020 Aug 14, 2020	BUY	$4.69 - $7.81 $7.5 Million - $12.5 Million	1,600,000 New	1,600,000 $10.2 Million

49.2K

Ticker CFRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,332,700
Market Cap $1.18M
Description
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clinical trials for the treatment of staphylococcus...

Get notified when there are updates to the investment portfolio of Bvf Inc, based on Form 13F filings with the SEC.

Stay updated on Bvf Inc with notifications on news.